Vaccine News and Research

Latest Vaccine News and Research

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second booster shot, it struck many covid experts as a self-serving remark without scientific merit. It also set off spasms of doubt over the country's objectives in its fight against the coronavirus.

21 Mar 2022

Study assesses human milk antibodies against common human coronaviruses following COVID-19 infection and vaccination

Study assesses human milk antibodies against common human coronaviruses following COVID-19 infection and vaccination

A recent study demonstrated that COVID-19 and its vaccination generates cross-reactive antibodies against human coronaviruses in lactating mothers.

21 Mar 2022

Study links the usage of oral polio vaccines with lower incidence of COVID-19

Study links the usage of oral polio vaccines with lower incidence of COVID-19

A study published in the journal PLOS ONE showed how countries using oral polio vaccine have a lower incidence of coronavirus disease (COVID-19) when compared to those using inactivated polio vaccine – suggesting that the oral vaccine may either prevent the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the individual level or slow down the transmission in the community.

21 Mar 2022

Response to COVID-19 boosters in seronegative multiple sclerosis patients

Response to COVID-19 boosters in seronegative multiple sclerosis patients

Researchers report humoral T-cell responses in seronegative MS patients after receiving a third COVID-19 booster vaccine dose.

20 Mar 2022

How does the non-structural protein 1 affect COVID-19 pathogenicity?

How does the non-structural protein 1 affect COVID-19 pathogenicity?

Researchers discuss the effects of the SARS-CoV-2 non-structural protein 1 (Nsp1), which binds to the ribosomal subunit thus inhibiting translation.

20 Mar 2022

Cov2clusters: Novel method for producing stable genomic clusters of SARS-CoV-2 cases

Cov2clusters: Novel method for producing stable genomic clusters of SARS-CoV-2 cases

Researchers present a novel method for producing stable genomic clustering of SARS-CoV-2 cases, Cov2clusters.

20 Mar 2022

Sinovac COVID vaccine shows modest efficacy against SARS-CoV-2 infection in children 3 to 5 years

Sinovac COVID vaccine shows modest efficacy against SARS-CoV-2 infection in children 3 to 5 years

Researchers investigate the efficacy of CoronaVac, COVID-19 vaccine developed by Sinovac Biotech, in children aged three to five years.

20 Mar 2022

Natural circulating antibodies last for at least seven months in children infected with COVID-19

Natural circulating antibodies last for at least seven months in children infected with COVID-19

Children previously infected with COVID-19 develop natural circulating antibodies that last for at least seven months, according to a new study led by researchers at UTHealth Houston.

18 Mar 2022

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

As SARS-CoV-2 has continued to evolve and outsmart existing treatments, scientists have not let up looking for ever-more effective tools to keep people safe and successfully recover from COVID-19, and to prepare for future outbreaks.

18 Mar 2022

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

A new study evaluated the specificity of antibody response elicited by the Delta variant of SARS-CoV-2.

18 Mar 2022

Innate and adaptive immune responses to BNT162b2 vaccination in mice

Innate and adaptive immune responses to BNT162b2 vaccination in mice

Researchers analyzed the innate and adaptive responses to the mRNA-based BNT162b2 COVID-19 vaccine in mice.

18 Mar 2022

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Researchers reported an epitope with high potency and breadth and demonstrated that a therapeutic antibody directed at this site neutralizes all SARS-CoV-2 variants.

18 Mar 2022

Study shows BCG vaccination reduces SARS-CoV-2-induced lung inflammation in hamsters

Study shows BCG vaccination reduces SARS-CoV-2-induced lung inflammation in hamsters

Researchers tested the effectiveness of the BCG vaccine in SARS-CoV-2-infected Syrian hamsters.

18 Mar 2022

Researchers argue that Omicron's lower severity is a coincidence

Researchers argue that Omicron's lower severity is a coincidence

Researchers raised concern regarding the emergence of new SARS-CoV-2 variants with unpredictable severity and immune evasion potential due to its ongoing fast-paced antigenic evolution.

18 Mar 2022

Breakthrough infection could provide broad protection against current SARS-CoV-2 variants of concern

Breakthrough infection could provide broad protection against current SARS-CoV-2 variants of concern

A delta breakthrough infection generates a potent and broad neutralizing antibody response in double vaccinated individuals, according to new research.

17 Mar 2022

Why does the SARS-CoV-2 Omicron variant escape immunity?

Why does the SARS-CoV-2 Omicron variant escape immunity?

Researchers reveal the underlying mechanism associated with the Omicron variant’s increased transmissibility and ability to evade immunity.

17 Mar 2022

Study finds high rates of cancer among men living with HIV

Study finds high rates of cancer among men living with HIV

Researchers with Case Western Reserve University have found that there are nearly twice as many men with cancer among men living with HIV (MLWH) compared to men who do not have the human immunodeficiency virus.

17 Mar 2022

Impact of new COVID vaccinations as novel variants emerge

Impact of new COVID vaccinations as novel variants emerge

Researchers explores the changing value of COVID-19 vaccines in a scenario of dynamic immunity and rapidly evolving variants of concern.

17 Mar 2022

Single dose of Pfizer vaccine reduces risk of SARS-CoV-2 infection in kids

Single dose of Pfizer vaccine reduces risk of SARS-CoV-2 infection in kids

Researchers discuss the efficacy of COVID-19 vaccines in young people and children when the SARS-CoV-2 Delta- and Omicron-dominant periods.

17 Mar 2022

BNT162b2 booster vaccination induces robust humoral and cellular immune responses

BNT162b2 booster vaccination induces robust humoral and cellular immune responses

Scientists evaluate the humoral and cellular immune responses in individuals who have received a third booster dose of mRNA-based COVID-19 vaccine.

17 Mar 2022

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.